Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Fox

Showing results (21-30 of 85) with videos related to

Pageof 9
Sort By:
Haematologica|November 20, 2025
JAK inhibitor selection in challenging scenarios of myelofibrosis: a reviewPankit Vachhani, Ruben Mesa, John Mascarenhas, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|May 26, 2018
Soluble B7-H4 blood serum levels are elevated in women at high risk for preeclampsia in the first trimester, as well as in patients with confirmed preeclampsiaPawel Mach, Luisa Nolte-Boenigk, Leonie Droste, et al.
Leukemia|May 13, 2020
Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapyJuan C Nieto, Elisa Roldán, Isabel Jiménez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 15, 2019
Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell TransplantationBeatriz Guglieri-Lopez, Alejandro Perez-Pitarch, Irene Garcia-Cadenas, et al.
Journal of Medical Virology|July 5, 2023
Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept studyCarlos Solano de la Asunción, Estela Giménez, Juan Carlos Hernández-Boluda, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 12, 2017
A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease ProphylaxisJosé Luis Piñana, Alejandro Perez-Pitarch, Irene Garcia-Cadenas, et al.
Ejhaem|February 26, 2024
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosisStephen T Oh, Srdan Verstovsek, Vikas Gupta, et al.
Transfusion Medicine Reviews|March 26, 2018
Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Español de Trasplante Hematopoyetico (GETH)Marta González-Vicent, Jaime Sanz, José Luis Fuster, et al.
Bone Marrow Transplantation|February 9, 2019
Author Correction: Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantationGuillermo Ortí, Irene García-Cadenas, Lucia López-Corral, et al.
Hematological Oncology|March 18, 2026
Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE)Francesco Passamonti, James M Foran, Anand Tandra, et al.
Pageof 9

Showing results (21-30 of 85) with videos related to

Sort By:
Pageof 9
Haematologica|November 20, 2025
JAK inhibitor selection in challenging scenarios of myelofibrosis: a reviewPankit Vachhani, Ruben Mesa, John Mascarenhas, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|May 26, 2018
Soluble B7-H4 blood serum levels are elevated in women at high risk for preeclampsia in the first trimester, as well as in patients with confirmed preeclampsiaPawel Mach, Luisa Nolte-Boenigk, Leonie Droste, et al.
Leukemia|May 13, 2020
Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapyJuan C Nieto, Elisa Roldán, Isabel Jiménez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 15, 2019
Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell TransplantationBeatriz Guglieri-Lopez, Alejandro Perez-Pitarch, Irene Garcia-Cadenas, et al.
Journal of Medical Virology|July 5, 2023
Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept studyCarlos Solano de la Asunción, Estela Giménez, Juan Carlos Hernández-Boluda, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 12, 2017
A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease ProphylaxisJosé Luis Piñana, Alejandro Perez-Pitarch, Irene Garcia-Cadenas, et al.
Ejhaem|February 26, 2024
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosisStephen T Oh, Srdan Verstovsek, Vikas Gupta, et al.
Transfusion Medicine Reviews|March 26, 2018
Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Español de Trasplante Hematopoyetico (GETH)Marta González-Vicent, Jaime Sanz, José Luis Fuster, et al.
Bone Marrow Transplantation|February 9, 2019
Author Correction: Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantationGuillermo Ortí, Irene García-Cadenas, Lucia López-Corral, et al.
Hematological Oncology|March 18, 2026
Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE)Francesco Passamonti, James M Foran, Anand Tandra, et al.
Pageof 9